Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models S. Sánchez-Gómez, J. Alfón, N. Ardanaz, B. Gil-Torregrosa, A. Fernández, E. Carceller, L. Gómez, D. Balsa, X. Bartrolí, M. Merlos (Palau-solità i Plegamans, Spain)
Source: Annual Congress 2010 - Models of airways disease
Session: Models of airways disease Session type: E-Communication SessionNumber: 3707
Disease area: Airway diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Sánchez-Gómez, J. Alfón, N. Ardanaz, B. Gil-Torregrosa, A. Fernández, E. Carceller, L. Gómez, D. Balsa, X. Bartrolí, M. Merlos (Palau-solità i Plegamans, Spain). Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models. Eur Respir J 2010; 36: Suppl. 54, 3707
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
CS-003, a novel triple neurokinin receptor antagonist, inhibits symptoms of respiratory diseases models in guinea pigs Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Alpha-7 nicotinic receptor stimulation reduces airway inflammation in a murine model of asthma Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Metabolism of ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
A dual-acting muscarinic antagonist, ß2 -agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Pharmacological treatment of asthma today Source: Eur Respir J 2001; 18: 34S-40S Year: 2001
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist, Viozan™ (AR-C68397AA) improves quality of life and perception of efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
A phase I inhalation study on ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
Protective effect of a protein epitope mimetic (PEM) CCR10 antagonist, POL7085, in an allergic model of asthma Source: Annual Congress 2011 - Translational models of airway disease Year: 2011